Sino Biopharmaceutical 2021 First Quarterly Profit attributable to Owners of the Parent Soars 118.5% to RMB1.91 Billion
Contribution of Sales of New Products to Revenue Rises to 47.4%
Driving Revenue Up by 16.4%
HONG KONG, May 24, 2021 - (ACN Newswire) - Sino Biopharmaceutical Limited ( Sino Biopharmaceutical or the Company , together with its subsidiaries, the Group ) (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited first quarterly results for the three months ended 31 March 2021.
Development Highlights Chia Tai - Tianqing Pharmaceutical Group Co. Ltd. ( CT Tianqing ), a member company of the Group, and Beijing-based Genetron Holdings Limited (NASDAQ: GTH) signed a strategic cooperation agreement on early screening of liver cancer. The two parties will work together in the next three years in selected areas in the country to serve those at high risk of developing liver cancer, including Hepatitis B carriers a
Unichem Laboratories gained 1.15% to Rs 280.85 after the company said it received US drug regulator s approval for celecoxib capsules, an anti-inflammatory drug.
In a regulatory filing made during market hours today, the company said that it had received ANDA approval for its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg from the United States Food and Drug Administration (US FDA). The product is a generic version of Celebrex capsules of G.D. Searle LLC, Division of Pfizer Inc.
Celecoxib capsules are indicated for treatment of osteoarthritis, rheumatoid arthritis juvenile rheumatoid arthritis, ankylosing spondylitis, acute pain and primary dysmenorrhea. The product will be commercialized from Unichem s Goa Plant, the company said in a statement.
Key equity barometers hit fresh intraday low as selling intensified in mid-afternoon trade. At 14:24 IST, the barometer index, the S&P BSE Sensex, was down 233.96 points or 0.47% to 49,283.15. The Nifty 50 index lost 66.70 points or 0.46% to 14,496.75.
Investors continued to monitor the developments on the US political front as the US House of Representatives is expected to vote on an impeachment motion against President Trump today.
The broader market underperformed the benchmark indices. The S&P BSE Mid-Cap index fell 1.13%. The S&P BSE Small-Cap index slipped 0.79%.
Sellers outpaced buyers. On the BSE, 1051 shares rose and 1957 shares fell. A total of 149 shares were unchanged.